Monika Fischer,Alexander Khoruts
Monika Fischer
Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis [0.03%]
生物制剂和小分子药物治疗中重度溃疡性结肠炎患者的疗效与安全性：系统评价与网络Meta分析
Juan S Lasa,Pablo A Olivera,Silvio Danese et al.
Juan S Lasa et al.
Background: There is a growing armamentarium for the treatment of moderate-to-severe ulcerative colitis. We aimed to compare the relative efficacy and safety of biologics and small molecule drugs for the treatment of pati...
Integrating novel therapies into the management of moderate-to-severe ulcerative colitis: challenges and opportunities [0.03%]
将新型疗法整合到中重度溃疡性结肠炎管理中的挑战与机遇
Christopher Ma,May Y Choi
Christopher Ma
Deep neural network for video colonoscopy of ulcerative colitis: a cross-sectional study [0.03%]
溃疡性结肠炎视频结肠镜检查的深度神经网络：一项横断面研究
Kento Takenaka,Toshimitsu Fujii,Ami Kawamoto et al.
Kento Takenaka et al.
Background: A combination of endoscopic and histological evaluation is important in the management of patients with ulcerative colitis. We aimed to adapt our previous deep neural network system (deep neural ulcerative col...
Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study [0.03%]
在荷兰基于便免疫化学检测的筛查项目实施前后结直肠癌发病率、死亡率、肿瘤特征和治疗情况的人群研究
Emilie C H Breekveldt,Iris Lansdorp-Vogelaar,Esther Toes-Zoutendijk et al.
Emilie C H Breekveldt et al.
Background: In 2014, a population-based colorectal cancer (CRC) screening programme was stepwise implemented in the Netherlands comprising faecal immunochemical testing once every 2 years, with a cutoff value for positivi...
Observational Study
The lancet. Gastroenterology & hepatology. 2022 Jan;7(1):60-68. DOI:10.1016/S2468-1253(21)00368-X 2022
Interim evaluation of the colorectal cancer screening programme in the Netherlands [0.03%]
荷兰结直肠癌筛查项目的中期评估
Michael Hoffmeister
Michael Hoffmeister
J Calvin Coffey,Kevin G Byrnes,Dara John Walsh et al.
J Calvin Coffey et al.
Over the past 5 years, systematic investigation of the mesenteric organ has expanded and shown that the mesentery is the organ in and on which all abdominal digestive organs develop and remain connected to. In turn, this observation has cla...
Effect of prophylactic endoscopic clip placement on clinically significant post-endoscopic mucosal resection bleeding in the right colon: a single-centre, randomised controlled trial [0.03%]
预防性内镜夹在右结肠内镜黏膜切除术后临床显著出血中的作用：单中心随机对照试验
Sunil Gupta,Mayenaaz Sidhu,Neal Shahidi et al.
Sunil Gupta et al.
Background: Endoscopic mucosal resection (EMR) is a cornerstone in the management of large (≥20 mm) non-pedunculated colorectal polyps. Clinically significant post-EMR bleeding occurs in 7% of cases and is most frequentl...
Randomized Controlled Trial
The lancet. Gastroenterology & hepatology. 2022 Feb;7(2):152-160. DOI:10.1016/S2468-1253(21)00384-8 2022
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial [0.03%]
ETROLIZUMAB作为先前接受过肿瘤坏死因子抑制剂治疗的溃疡性结肠炎诱导和维持治疗的III期随机对照试验（HICKORY）
Laurent Peyrin-Biroulet,Ailsa Hart,Peter Bossuyt et al.
Laurent Peyrin-Biroulet et al.
Background: Etrolizumab is a gut-targeted, anti-β7 integrin, monoclonal antibody. In an earlier phase 2 induction study, etrolizumab significantly improved clinical remission compared with placebo in patients with modera...
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study [0.03%]
艾托利珠单抗对比英夫利昔单抗治疗中重度活动性溃疡性结肠炎（GARDENIA）：一项随机、双盲、安慰剂对照、三期研究
Silvio Danese,Jean-Frederic Colombel,Milan Lukas et al.
Silvio Danese et al.
Background: Etrolizumab is a gut-targeted anti-β7 integrin monoclonal antibody. In a previous phase 2 induction study, etrolizumab significantly improved clinical remission versus placebo in patients with moderately to s...